Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Xin Qiu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1523-8209; OpenAlex author ID A5044406679. Sources: OpenAlex.

Their work

Papers
13 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 8 papers · 2023: 1 paper · 2024: 2 papers

Papers 13

  1. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, pha… Co-author DOI 10.3389/fimmu.2024.1210859↗
  2. [A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China]. First author DOI 10.3760/cma.j.cn112152-20231223-00383↗
  3. Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer. Co-author DOI 10.1080/21645515.2023.2178791↗
  4. MACC1 promotes pancreatic cancer metastasis by interacting with the EMT regulator SNAI1. Co-author DOI 10.1038/s41419-022-05285-8↗
  5. Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort. Co-author DOI 10.1080/21645515.2022.2143154↗
  6. LncRNA A2M-AS1 Promotes Ferroptosis in Pancreatic Cancer via Interacting With PCBP3. Co-author DOI 10.1158/1541-7786.mcr-22-0024↗
  7. Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report. Co-author DOI 10.3389/fimmu.2022.799026↗
  8. Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic… Co-author DOI 10.3389/fonc.2022.782730↗
  9. Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy. First author DOI 10.3389/fonc.2022.844527↗
  10. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiot… Co-author DOI 10.3389/fonc.2022.879661↗
  11. Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.898119↗
  12. AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study. First author DOI 10.3389/fonc.2021.693386↗
  13. Identification of Hub Prognosis-Associated Oxidative Stress Genes in Pancreatic Cancer Using Integrated Bioinformatics Analysis. Co-author DOI 10.3389/fgene.2020.595361↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Changchang Lu · 9 shared papers, 2021–2024 · strength 1.34
  2. Baorui Liu · 9 shared papers, 2021–2024 · strength 1.34
  3. Juan Du · 7 shared papers, 2021–2024 · strength 1.09
  4. Qiao-Li Wang Wang · 4 shared papers, 2022–2024 · strength 0.67
  5. Fan Tong · 3 shared papers, 2022–2024 · strength 0.52
  6. Huizi Sha · 3 shared papers, 2021–2024 · strength 0.50
  7. Shanyu Qin · 3 shared papers, 2020–2022 · strength 0.50
  8. Lei Wang · 3 shared papers, 2022 · strength 0.37
  9. Yudong Qiu · 3 shared papers, 2022 · strength 0.37
  10. Qi Li · 3 shared papers, 2022 · strength 0.37
  11. Xianglian Zhang · 2 shared papers, 2022 · strength 0.35
  12. Zhan Shi · 2 shared papers, 2022–2023 · strength 0.34
  13. Haixing Jiang · 2 shared papers, 2020–2022 · strength 0.33
  14. Linxi Zhu · 2 shared papers, 2022 · strength 0.25
  15. Juan Du · 2 shared papers, 2022 · strength 0.25
  16. Jun Chen · 2 shared papers, 2022 · strength 0.25
  17. Yu Cen · 1 shared paper, 2022 · strength 0.16
  18. Juan Liu · 1 shared paper, 2022 · strength 0.16
  19. Juan Du · 1 shared paper, 2024 · strength 0.15
  20. Hua Jiang · 1 shared paper, 2024 · strength 0.15
  21. Jun Wu · 1 shared paper, 2024 · strength 0.15
  22. B R Liu · 1 shared paper, 2024 · strength 0.15
  23. Jie Shao · 1 shared paper, 2022 · strength 0.14
  24. Xiaoling Gong · 1 shared paper, 2022 · strength 0.14
  25. Yujie Zhou · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.